DEF: Lyra Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Maintain Nasdaq Listing

Lyra Therapeutics is asking stockholders to approve a reverse stock split proposal at its upcoming annual meeting to maintain its Nasdaq listing and potentially facilitate future capital raising.

Summary

• Lyra Therapeutics is holding its Annual Meeting of Stockholders on May 14, 2025, virtually.
• Stockholders will vote on several proposals, including the election of two Class II Directors, ratification of the appointment of BDO USA, P.C. as the independent registered public accounting firm, and approval of a reverse stock split.
• The reverse stock split proposal seeks authorization to effect a split at a ratio ranging from 1-for-10 to 1-for-50, to be determined by the Board of Directors.
• The Board believes the reverse stock split is necessary to maintain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• As of April 3, 2025, Lyra's common stock closed at $0.11 per share.
• The company received notification from Nasdaq regarding non-compliance with the minimum bid price rule and has until July 14, 2025, to regain compliance.
• The reverse stock split could also help facilitate the company's ability to raise new equity capital and stimulate investor interest.
• The Board is also seeking approval to adjourn the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes to approve the reverse stock split proposal.

Sentiment

Score: 4

Explanation: The document is primarily factual, but the need for a reverse stock split and the mention of potential delisting suggest underlying financial challenges. The language is cautiously optimistic about the potential benefits of the reverse stock split, but acknowledges the risks.

Positives

• Maintaining the Nasdaq listing could improve investor confidence and facilitate future capital raising.
• A higher stock price may attract a broader range of institutional investors.
• The reverse stock split could improve the perception of the company's stock as an investment security.
• Continued Nasdaq listing qualifications for our Common Stock, can help attract, retain, and motivate employees and members of our Board.

Negatives

• The reverse stock split may not result in a sustained increase in the stock price.
• The reverse stock split could negatively impact the market price of the common stock if investors view it unfavorably.
• There is no guarantee that the company will be able to continue to satisfy Nasdaq's additional criteria for continued listing even if the reverse stock split is successful.
• The reverse stock split may result in some stockholders owning odd-lots of less than 100 shares of our Common Stock.

Risks

• The reverse stock split may not be sufficient to maintain compliance with Nasdaq listing requirements.
• The company's ability to raise additional capital depends on demonstrating a path to long-term profitable growth and market conditions.
• Failure to raise additional capital could have a material adverse effect on the company's ability to meet its short and long-term liquidity needs.
• The sale of additional equity would result in significant dilution to our stockholders.

Future Outlook

The company's future depends on its ability to maintain its Nasdaq listing, raise additional capital, and demonstrate a path to long-term profitable growth.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from major exchanges due to low stock prices. The success of a reverse stock split depends on various factors, including market conditions and investor sentiment.

Comparison to Industry Standards

• Many companies in the biotechnology industry have used reverse stock splits to regain compliance with Nasdaq listing requirements.
• Comparable companies that have recently undertaken reverse stock splits include [hypothetical company A] and [hypothetical company B].
• The typical range for reverse stock splits is between 1-for-2 and 1-for-10, but Lyra is seeking approval for a wider range of 1-for-10 to 1-for-50, indicating a more significant concern about its stock price.

Related Party Transactions

• Entities affiliated with Perceptive Advisors, LLC are shareholders of both Lyra Therapeutics and LianBio.
• Former directors Konstantin Poukalov and Michael Altman are Managing Directors at Perceptive Advisors, LLC.
• The company entered into a Securities Purchase Agreement with investors, including Perceptive Advisers, LLC and North Bridge Venture Partners, which are 5% or greater holders of the company's common stock and entities with which certain of the company's directors are related.
• The company entered into an Amendment No. 1 to the Ninth Amended and Restated Investor Rights Agreement with certain Investors affiliated with Perceptive Advisors and North Bridge Venture Partners.

Stakeholder Impact

• The reverse stock split will reduce the number of outstanding shares of common stock.
• The reverse stock split may affect the market price and liquidity of the company's stock.
• The company's ability to raise additional capital will impact its ability to fund operations and achieve its business objectives.
• The company's employees and directors who are compensated in the form of our equity-based securities may be less incentivized and invested in the Company if we are no longer listed on Nasdaq.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on May 14, 2025.
• The Board of Directors will determine whether to implement the reverse stock split and at what ratio, based on market conditions and other factors.
• The company must regain compliance with Nasdaq's minimum bid price requirement by July 14, 2025.

Key Dates

Keywords

reverse stock split, Nasdaq, minimum bid price, proxy statement, annual meeting, capital raising, stockholders, directors, BDO USA, listing compliance, Lyra Therapeutics